Biogen Turns A Corner As New Launches Offset MS Sales Declines

Overall Revenue Guidance Adjusted Positively

Leqembi for early Alzheimer’s, Skyclarys for Friedreich’s ataxia and Zurzuvae for postpartum depression meet or exceed Biogen’s internal sales expectations.

Red car on the side of the highway. Road trip.
Biogen product revenue turned a corner into positive territory in Q2; total revenue was flat • Source: Shutterstock

The “Fit for Growth” strategy that Biogen, Inc. CEO Christopher Viehbacher and his executive team put into place last year to trim $1bn in costs and reinvest the savings into research and development as well as business development seems to finally be paying off. The firm reported product sales growth for the second quarter, which the company has been seeking for years while revenue from its multiple sclerosis portfolio has largely been in decline.

Key Takeaways

  • Biogen delivered flat total revenue and increased product revenue in the second quarter and increased its full-year guidance slightly, for the first positive quarter in years.

While both products are rising from a small base, sales of the Eisai Co., Ltd.-partnered anti-amyloid antibody Leqembi (lecanemab)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip